Allosteric inhibitors—such as the EGFR allosteric inhibitor 045J (EAI045J) and the allosteric, orally active EGFR inhibitor JBJ-04-125-02—bind to the inactive conformation of EGFR and block its activity, thereby inhibiting the proliferation of cell lines and tumor growth in preclinical models with L858R/T790M- and L858R/T790M/C797S-mutated EGFR, either alone or in combination with an EGFR antibody[48-50]. Here, EGFR is linked to neoplasm.